INTRODUCTION
Biological thiols are challenging analytes. They posses similar structures, exhibit complex redox chemistry and are transparent in the visible spectral region. Over 50 thiol-reactive reagents are currently sold 1 . These typically contain universal electrophilic alkylating groups and are therefore nonselective for specific thiols. Many of these reagents must be handled with caution to prevent unwanted degradation and side-product formation. For instance, monobromobimane is unstable in H 2 O (ref. 2) , iodoacetamides are cross-reactive with histidine, tyrosine and methionine 1 , o-phthalaldehyde adducts exhibit high photoinstability 3 and maleimide labeling produces unwanted rearrangements of conjugates 4 . Due to the difficulties involved in thiol detection, determinations using colorimetric or fluorimetric reagents must be carried out in conjunction with separations 5 . There are numerous other procedures, which include chromatographic separations, immunoassays and enzymatic assays, and electrochemical, mass spectrometric and flow-injection technologies 6, 7 .
Elevated plasma levels (412-15 mM) of the thiol amino-acid homocysteine (Hcy) have been associated with increased risk of myocardial infarction, stroke and venous thromboembolism. Hcy has also been linked to increased risk of Alzheimer's disease, neural tube defects, complications during pregnancy, inflammatory bowel disease and osteoporosis [7] [8] [9] [10] . In addition to analytical HPLC with a derivatization step (vide supra), gas chromatography/mass spectrometry (GC-MS) and commercial immunoassays (e.g., the fluorescence polarization immunoassay run on Abbott's Imx and AxSYM platforms 11, 12 ) are often used to monitor Hcy. GC-MS requires instrumentation that is not typically applied at point-of-care. The immunoassays require enzymes, antibodies and biomolecules that are expensive and intrinsically unstable; therefore, careful attention to storage conditions is required.
The protocol described here is based on the kinetically favored formation of the alpha-amino carbon-centered radical of Hcy, which allows for the selective reduction of methyl viologen dication to its corresponding radical cation [13] [14] [15] (Fig. 1) . This characteristic reduction mechanism has proven useful in promoting the selective development of chromogen solution color by Hcy. Other commonly occurring thiols (such as cysteine and glutathione) as well as other amino acids do not produce interference 14, 15 . The method should be suitable for those who require a highly selective and simple off-to-on colorimetric test for detecting threshold levels of Hcy in its reduced (i.e., thiol rather than disulfide) form. Protection from air is not necessary during the assay; we believe that this is because dissolved O 2 , which would quench the radical reactions involved (Fig. 1) , is eliminated upon heating. All reagents are commercially available and relatively inexpensive. The protocol is illustrated using commercial reconstituted human blood plasma as a matrix. This method should also be suitable for monitoring reduced Hcy in other biological matrices, such as urine. Changes in reagent and/or buffer concentration allow for adjustment to higher Hcy threshold detection limits 15 Figure 1 | Hcy undergoes a thiyl radical to carbon radical rearrangement more readily than other biothiols. This is attributed to the favored formation of a five-membered ring (H-atom transfer) transition state, as opposed to fourmembered and nine-membered ring transition states as in the cases of cysteine and glutathione, respectively. Captodative stabilization of the alpha-amino carbon-centered radical renders the alpha C-H bond weaker than the S-H bond by B4 kcal/mol. Alpha-amino-acid carbon radicals are well-known strong reductants. Favored formation of the reducing alpha-amino radical in the case of Hcy allows for the selective reduction of weakly oxidizing chromogens, such as methyl viologen dication at neutral pH. 3| Add 0.1 ml Tris(hydroxymethyl)aminomethane buffer 0.5 M, pH 7 with a 1-ml plastic syringe.
4| Add 0.5 ml reconstituted plasma with a 1-ml plastic syringe.
5| Add 3.5 ml Hcy standard solution using a 10 ml glass microsyringe (the final concentration of Hcy should be 5 mM).
6| Close the vial tightly (using the appropriate screw cap).
7| Place the vial on the hot plate.
8| Shake the vial twice during the first minute of heating. ! CAUTION Handle with care as burns are possible. Wear gloves and safety glasses.
9| A faint blue color will develop in the refluxing solution after 4 min (the air stream entering the fume hood will moderately cool the walls of the vial being heated prompting solvent condensation). m CRITICAL Run a replicate; be sure that heating is uniform if running samples concurrently. 10| Repeat Steps 1-9 for additions of 7, 10.5 and 21 ml Hcy standard solution (the final concentrations of Hcy should be 10, 15 and 30 mM, respectively). Different visual color intensities will be obtained (Fig. 1). 11| Run a control sample with no Hcy added.
12| Run a sample with the addition of 10 ml cysteine standard solution (the final concentration of cysteine should be 450 mM) to rule out interferences. Table 1 . Figure 2 shows that solutions containing Hcy can be visually distinguished from the blank plasma sample and the cysteinecontaining control solutions. As the concentration of Hcy is increased, the solution color intensifies. 
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